跳至主要内容
临床试验/ACTRN12624000270516
ACTRN12624000270516尚未招募4 期

The effect of substantial weight loss with tirzepatide on heart failure with preserved ejection fraction in people with obesity

Baker Heart and Diabetes Institute0 个研究点目标入组 30 人开始时间: 2024年3月18日最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 80 Years(—)
性别
All

入选标准

  • Are greater than 18 years old,
  • Have a BMI of 30 or more, or a BMI of 27 or more and at least one weight-related complication (e.g., hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease),
  • Report one or more unsuccessful dietary effort to lose weight.

排除标准

  • Change in body weight of more than 5 kg within 90 days before screening
  • Previous or planned surgical treatment for obesity
  • Treatment with a medication that promotes weight loss within 90 days before screening
  • Ejection fraction <50% (current or prior)
  • Significant valvular heart disease (greater than mild stenosis, greater than moderate regurgitation)
  • Pulmonary arterial hypertension
  • Constrictive pericarditis
  • Primary cardiomyopathies
  • Heart transplantation
  • Significant pulmonary disease
  • History of pancreatitis
  • Previous bariatric surgery
  • Diagnosis of gastroparesis
  • Diagnosis of cancer within the past 5 years (excluding skin cancers)
  • Personal or family history of medullary thyroid cancer
  • Patients not eligible for Medicare
  • Patients who are not fluent in English.

研究者

相似试验